Comparison
Octreotide vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
83150-76-9
2023788-19-2
Molecular weight
1019.24 g/mol
4813 g/mol
Half-life
1.7 h
116 h
Sequence
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
3
of which in humans
4
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
2
2